ライフサイエンスコーパス: salmonella vaccine

1 ent in L-Sel(-/-) mice immunized with either Salmonella vaccine.

2 strategy for the development of multivalent Salmonella vaccines.

3 sed as a tool for guiding the development of Salmonella vaccines.

4 ield safe efficacious recombinant attenuated Salmonella vaccines.

5 context of the heterologous 987P fimbriae on Salmonella vaccines.

6 uce EAE and orally treated with one of three Salmonella vaccines 6 days postchallenge.

7 re, we constructed and evaluated an improved Salmonella vaccine against M. tuberculosis.

8 Recombinant attenuated Salmonella vaccines against avian coccidiosis were devel

9 These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to eff

10 Newly attenuated Salmonella vaccine constructs expressing TGEV S protein

11 The experimental Salmonella vaccine expressing colonization factor Ag I p

12 Oral immunization of mice with a Salmonella vaccine expressing colonization factor antige

13 Treatment with an anti-inflammatory Salmonella vaccine expressing enterotoxigenic Escherichi

14 mmunization of IL-4-/- mice with recombinant Salmonella vaccine expressing ToxC induced brisk mucosal

15 The development of a subunit Salmonella vaccine has been hindered by the absence of d

16 or the development of recombinant attenuated Salmonella vaccines in humans.

17 igen in hosts immunized with live attenuated Salmonella vaccines is related in part to the amount of

18 The development of safe live, attenuated Salmonella vaccines may be facilitated by detoxification

19 i.n. and possibly even oral delivery of live Salmonella vaccines may be unsafe although it is possibl

20 To assess the potential impact of imperfect Salmonella vaccines on prevalence over time and the erad

21 To turn such a recombinant attenuated Salmonella vaccine (RASV) strain into a universal DNA va

22 Live recombinant attenuated Salmonella vaccine (RASV) strains have great potential t

23 The use of recombinant attenuated Salmonella vaccine (RASV) strains is a promising strateg

24 AS) system for use in recombinant attenuated Salmonella vaccine (RASV) strains to enhance immune resp

25 study, we constructed recombinant attenuated Salmonella vaccine (RASV) strains with plasmids expressi

26 e included in various recombinant attenuated Salmonella vaccine (RASV) strains with RDAS derived from

27 al and delivered by a recombinant attenuated Salmonella vaccine (RASV).

28 delivered antigens by recombinant attenuated Salmonella vaccines (RASV) has been the subject of inten

29 nge when delivered by recombinant attenuated Salmonella vaccine (RASVs) strains.

30 Recombinant attenuated Salmonella vaccines (RASVs) have been used extensively t

31 taasdA allele in live recombinant attenuated Salmonella vaccines (RASVs) such as Salmonella enterica

32 The results show that imperfect Salmonella vaccines reduce the prevalence of Salmonella

33 show that a novel OVA-expressing recombinant Salmonella vaccine (Salmonella-OVA) elicits a Th1-biased

34 Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a si

35 effective control measures through applying Salmonella vaccines should be adjusted at different stag

36 ALB/c mice with 10(9) CFU of the recombinant Salmonella vaccine strain carrying pYA3494, immunoglobul

37 Our results indicate that the live Salmonella vaccine strain chi9447 harboring pYA4535 effi

38 The Salmonella vaccine strain expressing an unrelated antige

39 A live oral recombinant Salmonella vaccine strain expressing pneumococcal surfac

40 r location of the recombinant antigen in the Salmonella vaccine strain may contribute to augmenting i

41 Notably, we observed that a newly generated Salmonella vaccine strain not only conferred superior pr

42 The mutations were moved to an attenuated Salmonella vaccine strain to evaluate their effects on i

43 The mice immunized with the auxotrophic Salmonella vaccine strain with the deletion mutation Del

44 on for CA synthesis, was introduced into two Salmonella vaccine strains attenuated by auxotrophic tra

45 Candidate Salmonella vaccine strains synthesizing pneumococcal sur

46 ere constructed and introduced into isogenic Salmonella vaccine strains with or without arabinose-ind

47 In Salmonella vaccine strains with RDAS, the strain with th

48 ure conditions, and for many live attenuated Salmonella vaccine strains, the acid tolerance response

49 icity and efficacy of recombinant attenuated Salmonella vaccine strains.

50 ry useful for expressing foreign antigens in salmonella vaccine strains.

51 vaccine, inclusion of the msbB mutation in a Salmonella vaccine to deliver heterologous antigens has

52 -/-)) mice were orally immunized with either Salmonella vaccine vector or Salmonella vector-expressin

53 sponses to heterologous chimeric fimbriae on Salmonella vaccine vectors can be optimized by using pro

54 These results confirm that oral Salmonella vaccine vectors effectively deliver K99 fimbr

55 studies show that murine dams immunized with Salmonella vaccine vectors stably expressing K99 fimbria

56 ulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors.

57 The safety of dam mutant Salmonella vaccines was evaluated by screening within in

58 Attenuated and dephosphorylated Salmonella vaccines were able to induce adaptive immunit

59 t a viable option for developing a live oral Salmonella vaccine, while a wzy mutant that retains one